The DynCorp ruling is a welcome and much needed rebuke to international activist efforts to demonize U.S. industry through unfounded legal actions arising from international operations.
"A Florida federal judge on Wednesday nixed punitive damages from a lawsuit alleging Novartis Pharmaceuticals Corp.'s Aredia and Zometa bone drugs caused a woman to develop osteonecrosis of the jaw, finding that New Jersey law limiting punitive damages in such cases applies."
The American Lawyer journal highlights DynCorp's success as counter to Chevron's legal troubles in Ecuador.
The New Jersey Supreme Court has declined to hear a challenge to judgments for Novartis Pharmaceuticals Corp. in the first bellwether trial in consolidated litigation over claims the drugmaker's bone cancer drugs Aredia and Zometa caused jaw deterioration.
In an article published in Law360, Hollingsworth LLP spotlights the ban on BPA in a growing number of states.
A Texas federal judge . . . ruled against a cancer patient who sued Novartis Pharmaceuticals Corp. over a jaw injury she allegedly sustained after taking Zometa, handing Novartis the latest of several wins in multidistrict litigation over the bone drug in the past several months.
A Maryland federal judge ruled Wednesday that a woman cannot pursue punitive damages under New Jersey law for an injury allegedly caused by Novartis Pharmaceuticals Corp. bone drugs because they are preempted by federal law, a decision that makes it more difficult for plaintiffs in product liability actions to seek such damages from New Jersey-based drugmakers, experts say.
